The opinion of gynecologists on the management of early-stage, high-grade endometrioid endometrial cancer

Purpose of investigation: There is no consensus on the management of Stage I endometrioid endometrial cancer (EEC) with grade 3 histology. This study evaluates the opinion of gynecologists in The Netherlands on the management of Stage I, grade 3 EEC. Materials and Methods: Members of the Dutch Gynecologic Oncology Working Group were requested to complete a digital questionnaire on the management of Stage I, grade 3 EEC. Actual treatment of patients with Stage I, grade 3 EEC was assessed by analysis of PALGA, the Dutch Pathology Registry. Results: Most gynecologists prefer routine lymphadenectomy or complete staging (62.3%), while these were actually performed in 27.3% of the cases. Gynecologic oncologists are more likely to perform a lymphadenectomy than general gynecologists. There was a wide variation of clinical practice. Conclusion: The results of this study underline the need for additional research into management of Stage I, grade 3 EEC as well as the need for conclusive guidelines.

Endometrioid histology; Endometrial cancer; Grade 3; Questionnaire; Lymphadenectomy; Guidelines.

[1] “Dutch Cancer Figures” [Netherlands Cancer Registry Web site]. Available at: www.cijfersoverkanker.nl. Accessed January 2013.

[2] Nout R.A., Smit V.T., Putter H., Jurgenliemk-Schulz I.M., Jobsen J.J., Lutgens L.C., et al.: “Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial”. Lancet, 2010, 375. 816.

[3] Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma”. Lancet, 2000, 355. 1404.

[4] “Endometrial Cancer” [Oncoline cancer clinical practice guidelines Web site]. October 24, 2011. Available at: www.oncoline.nl/endometriumcarcinoom. Accessed January 2013.

[5] Casparie M., Tiebosch A.T., Burger G., Blauwgeers H., van de Pol A., van Krieken J.H., et al.: “Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive”. Cell. Oncol., 2007, 29. 19.

[6] Amant F., Mirza M.R., Creutzberg C.L.: “Cancer of the corpus uteri”. Int. J. Gynaecol. Obstet., 2012, 119, S110.

[7] Benedetti Panici P., Basile S., Maneschi F., Alberto Lissoni A., Signorelli M., Scambia G., et al.: “Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial”. J. Natl. Cancer Inst., 2008, 100. 1707.

[8] Kitchener H., Swart A.M., Qian Q., Amos C., Parmar M.K.: “Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study”. Lancet, 2009, 373. 125.

[9] Bendifallah S., Koskas M., Ballester M., Genin A.S., Darai E., Rouzier R.: “The survival impact of systematic lymphadenectomy in endometrial cancer with the use of propensity score matching analysis”. Am. J. Obstet. Gynecol., 2012, 206. 500 e1.

[10] “Uterine neoplasms” [National Comprehensive Cancer Network (NCCN) Web site]. February 21, 2013. Available at: www.nccn.org. Accessed February 2013.

[11] Delnevo C.D., Abatemarco D.J., Steinberg M.B.: “Physician response rates to a mail survey by specialty and timing of incentive”. Am. J. Prev. Med., 2004, 26. 234.